Targeting cisplatin-resistant human tumor cells with metabolic inhibitors

Cancer Chemotherapy and Pharmacology

Volumn 73, Issue 2, 2014, Pages 417-427

  Sullivan, Elizabeth J ^a   Kurtoglu, Metin ^a   Brenneman, Randall ^b   Liu, Huaping ^a   Lampidis, Theodore J ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

2 Deoxy d glucose; Cell death; Cisplatin resistance; Hexokinase

Indexed keywords

CISPLATIN; DEOXYGLUCOSE; FLUORODEOXYGLUCOSE; GLUTAMINE; HEXOKINASE; HEXOKINASE 1; HEXOKINASE ISOENZYME; LACTIC ACID; ONCOPROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANAEROBIC CELL CULTURE; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CANCER RECURRENCE; CANCER RESISTANCE; CELL DEATH; CELL HYPOXIA; CELL METABOLISM; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; FATTY ACID OXIDATION; GLYCOLYSIS; HUMAN; HUMAN CELL; LUNG CANCER; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DEOXYGLUCOSE; DRUG RESISTANCE, NEOPLASM; FEMALE; GLYCOLYSIS; HEXOKINASE; HUMANS; LACTIC ACID; LUNG NEOPLASMS; OVARIAN NEOPLASMS; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84896048826     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2366-8     Document Type: Article

References (22)

1. Yang Z, Schumaker L, Egorin M, Zuhowski E, Guo Z, Cullen KJ (2006) Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: possible role in apoptosis. Clin Cancer Res 12(19):5817-5825. doi:10.1158/1078-0432 (Pubitemid 44629614)
2. Leyton J, Latigo JR, Perumal M, Dhaliwal H, He Q, Aboagye EO (2005) Early detection of tumor response to chemotherapy by 3′-Deoxy-3′-[18F] fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model In vivo. Cancer Res 65:4202-4210. doi:10.1158/0008- 5472.CAN-04-4008 (Pubitemid 40775658)
3. Warburg O, Wind F, Negelein E (1927) Metabolism of Tumors in the Body. J Gen Physiol 8(6):519-530
4. Hanahan D, Weinberg R (2011) Hallmarks of cancer: the next generation. Cell 144:646-674. doi:10.1016/j.cell.2011.02.013
5. Liu H, Savaraj N, Priebe W, Lampidis TJ (2002) Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: a strategy for solid tumor therapy (Model C). Biochem Pharmacol 64(12):1745-1751. doi:10.1016/S0006-2952(02)01456-9 (Pubitemid 35351581)
6. Boutrid H, Jockovich ME, Murray TG, Pina Y, Feuer WJ, Lampidis TJ, Cebulla CM (2008) Targeting hypoxia, a novel treatment for advanced retinoblastoma. Invest Ophthalmol Vis Sci 49(7):2799-2805. doi:10.1167/iovs.08- 1751
7. Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K, Tidmarsh GF, De Young LR, Lampidis TJ (2004) 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res 64:31-34. doi:10.1158/0008-5472.CAN-03-3294 (Pubitemid 38114078)
8. Robey RB, Hay N (2006) Mitochondrial Hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. Oncogene 25:4683-4696. doi:10.1038/sj.onc.1209595 (Pubitemid 44187618)
9. Mathupala SP, Ko YH, Pedersen PL (2006) Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 25:4777-4786. doi:10.1038/sj.onc.1209603 (Pubitemid 44187625)
10. Pastorino JG, Shulga N, Hoek JB (2002) Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis. J Biol Chem 277(9):7610-7618. doi:10.1074/jbc.M109950200 (Pubitemid 34953160)
11. Kim JW, Dang CV (2005) Multifaceted roles of glycolytic enzymes. Trends Biochem Sci 30:142-150. doi:10.1016/j.tibs.2005.01.005
12. Majewski N, Nogueira V, Bhaskar P, Coy PE, Skeen JE, Gottlob K, Chandel NS, Thompson CB, Robey RB, Hay N (2004) Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol Cell 16:819-830. doi:10.1016/j.molcel.2004.11.014 (Pubitemid 39586539)
13. Ardehali H, Yano Y, Printz RL, Koch S, Whitesell RR, May JM et al (1996) Functional organization of mammalian hexokinase II retention of catalytic and regulatory function in both the NH- and COOH-terminal halves. J Biol Chem 271:1849-1852. doi:10.1074/jbc.271.4.1849
14. Maher JC, Wangpaichitr M, Savaraj N, Kurtoglu M, Lampidis TJ (2007) Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-D-glucose. Mol Cancer Ther 6(2):732-741. doi:10.1158/1535-7163.MCT-06- 0407 (Pubitemid 46332474)
15. Liang X, Finkel T, Shen D, Yin J, Aszalos A, Gottesman MM (2008) SIRT1 contributes in part to cisplatin resistance in cancer cells by altering mitochondrial metabolism. Mol Cancer Res 6(9):1499-1506. doi:10.1158/1541-7786. MCR-07-2130
16. Wangpaichitr M, Sullivan EJ, Theodoropoulos G, Wu C, You M, Feun L, Lampidis TJ, Kuo MT, Savaraj N (2012) The relationship of thioredoxin-1 and cisplatin resistance: its impact on ROS and oxidative metabolism in lung cancer cells. Mol Cancer Ther 11:604-615. doi:10.1158/1535-7163.MCT-11-0599
17. Berezhnoy A, Brenneman R, Bajgelman M, Seales D, Gilboa E (2012) Thermal stability of siRNA modulates aptamer- conjugated siRNA inhibition. Mol Ther Nucleic Acids 16(1):e51. doi:10.1038/mtna.2012.41
18. Maher JC, Krishan A, Lampidis TJ (2004) Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic vs aerobic conditions. Cancer Chemother Pharmacol 53(2):116-122. doi:10.1007/s00280-003-0724-7 (Pubitemid 38186989)
19. Raez LE, Papadopoulos K, Ricart AD, Chiorean EG, Dipaola RS, Stein MN, Rocha Lima CM, Schlesselman JJ, Tolba K, Langmuir VK, Kroll S, Jung DT, Kurtoglu M, Rosenblatt J, Lampidis TJ (2013) A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 71(2):523-530. doi:10.1007/s00280-012- 2045-1
20. Wintzell M, Löfstedt L, Johansson J, Pedersen AB, Fuxe J, Shoshan M (2012) Repeated cisplatin treatment can lead to a multiresistant tumor cell population with stem cell features and sensitivity to 3-bromopyruvate. Cancer Bio Ther 13(14):1454-1462. doi:10.4161/cbt.22007
21. Piña Y, Decatur C, Murray TG, Houston SK, Lopez-Cavalcante M, Hernandez E, Celdran M M, Shah N, Feuer W, Lampidis T (2012) Retinoblastoma treatment: utilization of the glycolytic inhibitor, 2-deoxy-2-fluoro-D-glucose (2-FG), to target the chemoresistant hypoxic regions in LHBETATAG retinal tumors. Invest Ophthalmol Vis Sci 53:996-1002. doi:10.1167/iovs.11-8265
22. Tajeddine N, Galluzzi L, Kepp O, Hangen E, Morselli E, Senovilla L, Araujo N, Pinna G, Larochette N, Zamzami N, Modjtahedi N, Harel-Bellan A, Kroemer G (2008) Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death. Oncogene 27:4221-4232. doi:10.1038/onc.2008.63 (Pubitemid 351969915)